Novel Treatment Options for T790M-Mutant Non-Small Cell Lung Cancer

Neelesh Sharma, MD, PhD
Published Online: May 8, 2014
Neelesh Sharma, MD, PhD Neelesh Sharma, MD, PhD

Assistant Professor Thoracic Oncology
University Hospitals/Case Comprehensive
Cancer Center
Case Western Reserve University

Abstract

First-generation, reversible, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and geftinib have become the standard of care and first-line treatment option for patients with non-small cell lung cancer (NSCLC) with activating EGFR mutations. Despite initial clinical benefit, overall efficacy of these agents is limited by emergence of drug-resistance mutations, including the gatekeeper T790M mutation. Substitution of methionine for threonine at position 790 of EGFR leads to increased affinity for adenosine triphosphate (ATP), causing resistance to competitive inhibition by reversible EGFR-TKIs. Second-generation, irreversible EGFR-TKIs were developed to overcome this resistance and demonstrated significant preclinical activity in mouse models of T790M-mutant lung cancer. However, these agents had limited success in clinical trials because of concurrent inhibition of wild-type EGFR and associated toxicity that prevented achieving adequate drug levels in plasma for sufficient inhibition of EGFR T790M. CO-1686 and AZD9291 are third-generation, irreversible T790M mutant-specific EGFR-TKIs with little activity on wildtype EGFR and robust activity in T790M preclinical models. In ongoing phase I clinical trials, both agents have shown promising responses in patients with EGFR-TKI-resistant tumors carrying T790M mutation.

Introduction

Developments in last decade have established a central role for epidermal growth factor receptor (EGFR) pathway in the treatment of non-small cell lung cancer (NSCLC). Initial observation that EGFR protein is highly expressed in various tumors, including lung cancer, led to the development of first-generation small molecule EGFR tyrosine kinase inhibitors (TKIs). Advances in structure-activity relationship (SAR) and molecular modeling made it easier to generate novel molecules that were complementary in shape and electrostatics to the EGFR kinase domain topography.1 A major breakthrough in this field was the discovery of 4-anilinoquinazolines (gefitinib, erlotinib, and lapatinib), which are potent and selective but reversible inhibitors of EGFR. The quinazoline ring binds in the adenine pocket with hydrogen bonds and the anilino ring binds in an adjacent, unique hydrophobic pocket, causing competitive inhibition for adenosine triphosphate (ATP) binding in the tyrosine kinase domain.2

Related Articles
The FDA has approved the VEGFR-2 inhibitor ramucirumab (Cyramza) in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumor has progressed during or following treatment with platinum-based chemotherapy.
The programmed death receptor-1 (PD-1) ligand, PD-L1, has become a viable target for immunotherapy in cancer, with multiple antibodies now in development.
Multiple trials are ongoing in NSCLC with immunotherapy agents. As with most cancers, however, there is also a need to identify which types of patients with NSCLC might benefit the most from these new therapies.
Vassiliki Papadimitrakopoulou, MD, discusses adverse events associated with immunotherapies for the treatment of lung cancer.
JTT Articles
HPV Test With Genotyping Supplants Pap Test
Dacomitinib Shows Responses in Subset of Head and Neck Cancer
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.